Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine
Preeclampsia Severe, Optic Nerve Sheath Diameter
About this trial
This is an interventional prevention trial for Preeclampsia Severe
Eligibility Criteria
Inclusion Criteria: aged18 to 40 years with at least 36 weeks gestation admitted with diagnosis of severe pre-eclampsia and scheduled to receive Magnesium Sulphate therapy before delivery Exclusion Criteria: Presence of ocular wound or Prior ocular surgery emergency cases, and evidence of fetal compromise HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet levels) Chronic hypertension Hyperthyroidism, and diabetes mellitus Presence of pre-existing chronic lung and/or cardiac diseases Presence of pre-existing chronic renal and/or hepatic diseases Presence of any chronic diseases of central nervous system. known allergies to the tested drug.
Sites / Locations
- Samar Rafik AminRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Group (D)
Group (C)
Patients will receive a loading dose of iv dexmedetomidine followed by a maintenance infusion.
patients will receive saline loading and infusion